Key Takeaways:
- Innovent's IBI363 won a third Breakthrough Therapy Designation in China.
- The drug targets an advanced colorectal cancer subtype resistant to immunotherapy.
- A Phase III trial is set to begin, accelerating its path to market.
Back
Innovent Wins 3rd Breakthrough Tag for Drug Targeting 95% of Colorectal Cancers
Innovent Biologics Inc. (HKEX: 01801) secured its third Breakthrough Therapy Designation for IBI363, a novel cancer drug designed to overcome immunotherapy resistance in a colorectal cancer subtype that accounts for approximately 95% of advanced cases.
"IBI363 is a promising next-generation IO agent by combining dual mechanisms—PD-1 blockade and IL-2-driven tumor-specific T-cell populations expansion—thus reshaping the tumor microenvironment," Dr. Hui Zhou, Chief R&D Officer of Oncology Pipeline at Innovent, said in a statement.
The designation from China's National Medical Products Administration (NMPA) is for IBI363 in combination with bevacizumab for microsatellite stable (MSS/pMMR) colorectal cancer patients who have failed at least two prior therapies. This follows two previous BTDs in China and two Fast Track Designations in the US for other cancers. Innovent plans to initiate a Phase III trial for the colorectal cancer indication in the near term.
The accelerated pathway is critical for Innovent as it targets a vast unmet need. Standard immunotherapies are largely ineffective against MSS/pMMR "cold tumors," creating a significant market opportunity. The designation de-risks a key asset being co-developed globally with Takeda, potentially speeding its entry into the world's second-largest pharma market.
A New Approach for "Cold Tumors"
IBI363 is a first-in-class PD-1/IL-2α-bias bispecific fusion protein. In simple terms, it performs two functions simultaneously. The PD-1 arm blocks a pathway that cancer cells use to hide from the immune system, a mechanism used by established immunotherapy drugs. The IL-2 arm selectively stimulates tumor-fighting T-cells, aiming to turn immunologically "cold" tumors that don't respond to treatment into "hot" tumors that do.
Early-stage clinical data presented at the 2025 ASCO conference showed that IBI363, combined with bevacizumab, had promising efficacy in heavily pre-treated patients. The NMPA's Breakthrough Therapy Designation is intended to expedite the development and review of drugs that show substantial improvement over existing therapies for serious conditions.
Pipeline and Partnerships
The new designation strengthens a key asset in Innovent's oncology pipeline. The company, founded in 2011, has 18 products on the market, five assets in Phase III or pivotal trials, and 14 other molecules in early-stage clinical development.
The global development and commercialization of IBI363 is shared with Takeda Pharmaceutical Company. Under a deal signed in October 2025, the two companies will co-develop and co-commercialize the drug in the U.S., while Takeda holds exclusive rights for the rest of the world outside of greater China. This partnership provides external validation and financial support for IBI363's broad development program across multiple cancer types, including non-small cell lung cancer and melanoma.
This article is for informational purposes only and does not constitute investment advice.
[1] Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer[2] Japanese Medtech Startup, CoreTissue BioEngineering, Initiates Randomized Controlled Cohort in the Clinical Trial for Anterior Cruciate Ligament (ACL) Reconstruction Treatment[3] SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts.
